• Pre-clinical company focused on reproductive health working with leading IVF groups in UK and Europe with medical advisors from Imperial and Harvard Medical School

• Funding will support scientific development of the company’s first diagnostic product – the world’s first non-invasive fertility diagnostic for the uterus – and its broader ML discovery platform for novel biomarkers focused on reproductive health

• US and European investors including Tiny VC, 33East VC, Arben Ventures, Transpose Platform and Entrepreneur First

Genie Fertility, a UK-based biotech startup focusing on reproductive health, is launching from stealth with $1.22m in pre-seed funding to announce the development of its first product, the world’s first non-invasive fertility diagnostic for uterus health.

Genie Fertility have discovered a number of novel fertility markers in the uterus lining that can actually be improved on with existing medical pathways.

“The health of the uterus lining accounts for up to 25% of fertility issues, but it has long been a blindspot for clinicians because it can only be accessed through an invasive and painful biopsy,” said Anoushka Menon, CEO of Genie Fertility. “Our pain-free non-invasive diagnostic changes that.”

Powered by Genie’s ML multi-omics discovery platform built on data from over 200,000 fertility patients, Genie Fertility’s first diagnostic test studies a range of molecular markers in the uterus lining through menstrual blood. These biomarkers offer crucial insight to clinicians, as menstrual blood is the monthly shedding of the uterus lining, and rich in reproductive health data.

“IVF is the gold-standard treatment for infertility, which affects 1 in 6 couples, but it fails 73% of the time and requires urgent innovation.” said Dr Andreas Hadjimitsis, Co-Founder and CTO of Genie Fertility. “A lot of the focus in fertility has been on sperm, egg and embryo health. We want to create a world where the uterus gets the same attention.”

Working with some of the largest IVF groups in the UK and Europe, and backed by medical advisors from Imperial College London and Harvard Medical School, Genie Fertility will use its discovery platform to develop further diagnostics and targeted therapeutics to improve outcomes for historically neglected reproductive conditions that affect millions of women of reproductive age.

The $1.22 million pre-seed round includes participation from both US and European investors, including Tiny VC, 33East VC, Arben Ventures, Transpose Platform and Entrepreneur First. The funding will support scientific development and validation of the company’s first diagnostic product, and foundational work on its broader AI discovery platform for reproductive health innovation.